Aesthetic plastic surgery · 2026
Comparison of Intradermal Injection with Mesotherapy of Botulinum Toxin Type A for Axillary Sweat Reduction: A Preliminary, Prospective, Randomized, Self-controlled Study.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Yan, Chen Xia, Tang Yujun, Chen Xinqi, Wang Junlin, Li Yiming
Аннотация
BACKGROUND: Relieving botulinum toxin type A (BoNT-A) injection-related pain is important for hyperhidrosis treatment. Till now, there is no report on the comparison of BoNT-A intradermal injection (BontAintra) and BoNT-A mesotherapy (BontAmeso).
OBJECTIVES: The purpose of this study was to investigate the effect, duration of efficacy, pain, and patients' satisfaction of BontAintra and BontAmeso.
METHODS: This preliminary, prospective, randomized, self-controlled study recruited subjects expecting to reduce axillary sweat. The subjects were randomized to receive a 50 U BontAintra on the left axillae and a 50, 60, or 70 U BontAmeso on the right axillae, respectively. The axillary sweat weight and hyperhidrosis severity scale (HDSS) on 2 weeks, 1 months, 4 months, and 6 months post-treatment were measured. The pain, satisfaction, and adverse events (AEs) were compared.
RESULTS: Thirty-one subjects were enrolled. According to the axillary sweat weight and HDSS, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy with the 50 U BontAintra. The efficacy of 50 and 60 U BontAmeso was comparable with the 50 U BontAintra on the 2 week follow-up, and the duration of efficacy was significantly shorter. The pain ratings with three dosages of BontAmeso were significantly lower than those with BontAintra. The subjects' satisfaction ratings with BontAmeso were significantly higher than those with BontAintra. No serious AEs occurred.
CONCLUSIONS: Compared with the 50 U BontAintra, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy, with significantly lower treatment-associated pain and higher satisfaction.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
OBJECTIVES: The purpose of this study was to investigate the effect, duration of efficacy, pain, and patients' satisfaction of BontAintra and BontAmeso.
METHODS: This preliminary, prospective, randomized, self-controlled study recruited subjects expecting to reduce axillary sweat. The subjects were randomized to receive a 50 U BontAintra on the left axillae and a 50, 60, or 70 U BontAmeso on the right axillae, respectively. The axillary sweat weight and hyperhidrosis severity scale (HDSS) on 2 weeks, 1 months, 4 months, and 6 months post-treatment were measured. The pain, satisfaction, and adverse events (AEs) were compared.
RESULTS: Thirty-one subjects were enrolled. According to the axillary sweat weight and HDSS, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy with the 50 U BontAintra. The efficacy of 50 and 60 U BontAmeso was comparable with the 50 U BontAintra on the 2 week follow-up, and the duration of efficacy was significantly shorter. The pain ratings with three dosages of BontAmeso were significantly lower than those with BontAintra. The subjects' satisfaction ratings with BontAmeso were significantly higher than those with BontAintra. No serious AEs occurred.
CONCLUSIONS: Compared with the 50 U BontAintra, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy, with significantly lower treatment-associated pain and higher satisfaction.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .